In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer

Gynecologic Oncology
V. E. Von GruenigenJ. M. Mathis

Abstract

To test the safety, efficacy, and toxicity of gene therapy using wild-type p53-expressing adenovirus (Ad-CMV-p53) in a nude mouse model with intraperitoneal (i.p.) 2774 human ovarian cancer cell line that contains a p53 mutation. An initial study of adenovirus tolerance was determined in nude mice by a single i.p. injection of increasing doses of Ad-CMV-p53. Nude mice were implanted with an LD100 dose of 1 x 10(7) cells. To study the efficacy and specificity of Ad-CMV-p53 treatment, the mice received treatment with different adenovirus constructs. One group received Ad-CMV-p53 and another group received a control adenovirus construct, Ad-CMV-beta gal. To study the treatment response to Ad-CMV-p53, the mice were divided into groups and received various treatment schedules of 1 x 10(8) pfu of Ad-CMV-p53. The mice tolerated Ad-CMV-p53 without adverse effects at doses of 1 x 10(8) pfu. The response to Ad-CMV-p53 showed significant survival duration in each dose regimen, with a survival time greater than that of untreated animals (P = 0.0173). However, no statistically significant survival advantage was observed between Ad-CMV-p53- and Ad-CMV-beta gal-treated mice. These studies show that at the adenovirus dose and administration re...Continue Reading

References

Nov 1, 1978·Cancer·R S FreedmanF Rutledge
Jul 1, 1977·The Journal of General Virology·F L GrahamR Nairn
Aug 1, 1990·Analytical Biochemistry·J Alam, J L Cook
Jan 1, 1994·Current Opinion in Oncology·T FujiwaraJ A Roth
Sep 15, 1993·Journal of the National Cancer Institute·M F KohlerA Berchuck
Oct 28, 1993·The New England Journal of Medicine·C C Harris, M Hollstein
Feb 15, 1993·Cancer·R C BastA Berchuck
May 14, 1993·Science·R C Mulligan
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J KupryjańczykD W Yandell

❮ Previous
Next ❯

Citations

Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·V. E. Von GruenigenJ. M. Mathis
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R. C. BastG. B. Mills
Aug 13, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K D Sloan Stakleff, V E Von Gruenigen
Apr 13, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K D Sloan StakleffV E Von Gruenigen
May 12, 2000·The Laryngoscope·L L Gleich
Jun 26, 2002·Cancer Gene Therapy·Richard E BullerMark Pegram
Oct 9, 2003·The Journal of Gene Medicine·Zhujun ZhangAkinobu Gotoh
Mar 16, 2001·Breast Cancer Research : BCR·P S ObermillerJ T Holt
Sep 21, 2020·Cancer Gene Therapy·Rebeca Gonzalez-PastorDavid T Curiel

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.